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Abstract
The phenotype imparted by expression of the HER2 gene in breast cancer and progress made in
modifying the disease's natural history through pharmacologically modulating its function has served
as a paradigm for rationally targeted therapy and personalized medicine. About 20–25% of breast
cancer cases are associated with HER2 gene amplification and overexpression, creating a distinct
subtype of breast cancer that is associated with more aggressive behaviour, higher likelihood of
overall and brain metastases, and differential responsiveness to certain hormonal and chemo-
therapeutic agents. Anti-HER2 monoclonal antibodies have led to significant improvements in survival
for both advanced and early stage HER2+ breast cancer, while newer agents, including other
antibodies and HER2 receptor tyrosine kinase inhibitors and signal transduction modulators, are
also demonstrating clinical activity and represent further opportunities to improve curability and
quality of life.
Introduction and context
Upon the recognition of the importance of HER2
amplification and overexpression in the outcome of
patients with early stage breast cancer, laboratory
experiments using anti-HER2 antibodies consistently
showed growth inhibitory effects, presumably due to
modulation of downstream signal transduction, but also
potentially due to activation of the immune system
against HER2 epitopes [1,2]. Phase I and II trials showed
that a humanized HER2 antibody, trastuzumab (trade
name Herceptin®), given as a single agent could lead to
transient - but in some cases, long-lived - responses in
15% of advanced breast cancer patients in the second
line setting and 26% of patients as first line therapy [3–
5]. A pivotal randomized trial showed that the addition
of trastuzumab to standard first line chemotherapy in
HER2+ advanced breast cancer can improve response
rates and time to disease progression (TTP) and also
improved median survival by a relative amount of 24%,
or an absolute median gain of 5 months, leading to the
approval of this drug in HER2+ metastatic breast cancer
(Figure 1) [6].
Systemic therapy used in the early stage adjuvant setting
has the potential to improve long-term curability, so the
logical extension of these findings was to compare the
addition of trastuzumab to standard chemotherapy in
patients with HER2+ early stage breast cancer, using
1 year of trastuzumab therapy - a length of time that was
arbitrary, but at least supported by safety data. Careful
cardiac screening and monitoring was incorporated into
all four major pivotal trials done worldwide. The two
North American trials [N9831 and National Surgical
Bowel and Breast Program (NSABP) B-31] used a
standard regimen of doxorubicin and cyclophosphamide
(AC) for four cycles every 3 weeks followed by paclitaxel
either every 3 weeks for four cycles or at a lower dose
every week for 12 weeks with or without trastuzumab.
Trastuzumab was given with paclitaxel at standard doses.
The N9831 trial contained a third arm in which
trastuzumab was given following paclitaxel. The Breast
Cancer International Research Group (BCIRG) 006 trial
used a control arm of AC followed by four cycles of
docetaxel. The second arm was administered trastuzu-
mab with docetaxel. A third arm used docetaxel and
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concurrently; this arm was based on preclinical synergy
noted in preclinical models with both these chemother-
apeutic agents and trastuzumab and was also testing
whether less cardiotoxicity might be observed with a
non-anthracycline arm. The HERA 3-arm study was more
permissive and allowed any pre- or postoperative
chemotherapy regimen of more than four cycles com-
pared to chemotherapy with either 1 or 2 years of
trastuzumab.
All these trials were stopped early or reported at early
interim analysis as the effect size was greater than
expected, with hazard ratios for recurrence-free survival
ranging from 0.48 to 0.67, and absolute differences in
disease-free survival at 3–4 years ranging from 5 to
12.8% [7–10]. Significant differences in overall survival
were also seen in all trials, and other findings of these
pivotal trials are shown on Table 1. Symptomatic cardiac
toxicity was seen in 0.4–3.8% of patients, with higher
rates seen with concurrent chemotherapy that included
an anthracycline,and recovery was seen in most cases [8–
11]. Higher age, lower pre-trastuzumab cardiac ejection
fraction and history of hypertension or use of anti-
hypertensive medications were noted as risk factors for
cardiac events, and most, but not all, patients recovered
from these side effects [11,12]. Based on these data,
trastuzumab has been approved with the regimens used
in the North American and BCIRG 006 trials for node-
positive and high risk node-negative HER2+ breast
cancer.
Recent advances
Currently, the use of trastuzumab is considered standard
therapy in the first line setting for advanced HER2+
breast cancer, typically in combination with chemother-
apy, but is also used as a single agent as initial or second
line therapy. There is some controversy about therapy
after progression on trastuzumab – the combination of
lapatinib and capecitabine is approved on the basis of a
randomized trial showing that this combination led to a
significant prolongation of TTP [13]. However, trastuzu-
mab plus capecitabine has also been found to prolong
TTP compared to capecitabine alone in patients who had
progression on trastuzumab-based therapy [14]. In the
adjuvant setting, individualized decision-making that
balances benefits against risks, particularly cardiomyo-
pathy, is warranted and generally this is indicated in
node-positive or high risk node-negative disease,
although other tumour and patient factors (tumour
grade, age, co-morbidities) all play a role. Only
combinations with chemotherapy have been tested in
early stage disease, so the optimal chemotherapy partner
remains to be defined – in the US, anthracycline and
taxane regimens are more commonly used. The use of
Figure 1. HER2 detection in tumour tissue and impact of
trastuzumab on survival when added to chemotherapy for
advanced HER2+ breast cancer
HER2 status is assessed either by (a) immunohistochemistry (IHC) level 3+,
or by (b) gene amplification, defined by fluorescent in situ hybridization
(FISH), where the average ratio of HER2 gene (red fluorochrome) to the
centromeric portion of chromosome 17 (blue fluorochrome) is ≥ 2.2. (c)
Survival is improved with the addition of trastuzumab to chemotherapy [6].
Table 1. Pivotal HER2-targeting adjuvant trials using trastuzumab
Trial/experimental
regimen
n Median f/u
(years)
HR DFS HR OS Absolute %
difference DFS
Absolute %
difference OS
CHF (%) Reference
NSABP B-31/N9831:
AC→TH
3,968 2.9 0.48 0.65 12.8 at 4 years 3.2 at 4 years 2.5–3.8 [6,7,10]
HERA: multiple→H 3,401 2 0.64 0.66 6.3 at 3 years 2.7 at 3 years 0.6 [8]
BCIRG 006: AC→DH 3,222 2 0.61 0.58 6 at 3 years 4 at 3 years 1.9 [9]
BCIRG 006: DCaH 3,222 2 0.67 0.66 5 at 3 years 2 at 3 years 0.4 [9]
A, doxorubicin; Absolute % difference DFS, absolute percentage difference in disease-free survival; Absolute % difference OS, absolute percentage difference
in overall survival; BCIRG, Breast Cancer International Research Group; C, cyclophosphamide; Ca, carboplatin; CHF, congestive heart failure (symptomatic);
D, docetaxel; H, trastuzumab (Herceptin); HERA, Herceptin Adjuvant; HR DFS, hazard ratio disease-free survival; HR OS, hazard ratio overall survival;
Median f/u, median follow-up; n, number of patients; NSABP, National Surgical Adjuvant Breast and Bowel Project; T, paclitaxel.
Page 2 of 4
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:20 http://F1000.com/Reports/Medicine/content/1/20trastuzumab alone or in combination with hormonal
therapy alone has not been tested in randomized trials.
Durations of less than 1 year have not been fully tested,
although an underpowered Finnish study, known as the
FinHer trial, showed efficacy when trastuzumab was
used in combination with chemotherapy for a short
period [15]. Therapy should be temporarily suspended
or permanently discontinued for any clinical cardiac
complications, and in some cases for subclinical decrease
in ejection fraction.
Newer HER2-targeted agents such as small molecule
kinase inhibitors are being tested, with lapatinib now
being tested both in advanced and early stage disease,
and HKI-272 in early phase trials for HER2+ advanced
breast cancer [16]. Pertuzumab, a new antibody that
inhibits dimerisation of HER2 with other HER family
members, has also shown activity in trastuzumab-
refractory disease [17], as has trastuzumab-DM1, an
immunotoxin [18,19]. Combining trastuzumab with
HSP90 inhibitors, which affect the trafficking and proper
folding of several proteins involved in signal transduc-
tion, has also yielded responses in trastuzumab-refrac-
tory cases [20].
Implications for clinical practice
The HER2 oncogene represents an important mediator of
breast carcinogensis and is a clinically relevant biomar-
ker. Targeting HER2 with the antibody trastuzumab has
been shown to improve outcome in both advanced and
early stage disease and represents a standard of care that
requires HER analysis of all breast cancer cases. Guide-
lines for HER2 interpretation and the need to use high-
volume and accredited laboratories are critical [21].
Estimations of the risk of recurrence along with hazard
reductions from clinical trials need to be juxtaposed
against cardiac and other side effects for optimal
individualized decision-making. In the advanced setting,
newer HER2-targeting agents will be tested more system-
atically as salvage therapy, and then in first line use with
the hopes that more activity, or less toxicity, might be
seen. It is not clear if it is best to use a combination of
HER2-directed therapies at the outset, or to wait until
there is evidence of clinical resistance. Well designed
tissue correlative studies may provide newer biomarkers
to predict responses to specific HER2-targeted drugs and
aid in decision-making as well as in identifying new
targets that could be addressed pharmacologically to
reverse resistance to trastuzumab or improve outcomes
when added to trastuzumab.
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